Under this background, the TLR3 mutation can be used as KRAS‐mutant CRC patients with good therapeutic targets, and in the context of KRAS mutations, environment is more effective, and the cut will further enhance its efficacy of TLR3, thus more particularly effective in KRAS mutations in patients with the queue 75. This evidence concerns the gene TLR3 and colorectal carcinoma.